Ernexa Therapeutics Inc. Common Stock
ERNA XNASAbout Ernexa Therapeutics Inc. Common Stock
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0 | $-4,009,000 | $-3.40 |
| Q1 2026 | $0 | $-5,506,000 | $-6.95 |
| FY 2025 | $0 | $-14,084,000 | $-2.24 |
| Q3 2025 | $0 | $-1,240,000 | $-0.15 |
Earnings & Analyst Ratings
TickerDaily Coverage
Get ERNA Alerts
Stay ahead with breaking news, price alerts, and expert analysis on Ernexa Therapeutics Inc. Common Stock.